• Partnership to launch “Access Accelerated”
  • TaNeDS Europe 2017
  • DS Library
  • DS Library
  • e-healthy recipe

Featured Stories

Who We Are

Who We Are

Daiichi Sankyo is a global pharmaceutical company with its corporate origin in Japan.
read more ...

Investor Relations

Investor Relations

Daiichi Sankyo to present at 35th annual J.P. Morgan Healthcare Conference.
read more ...

Featured News

Date
Description  
2017.01.19
Press Release
Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer PDF
2017.01.18
Press Release
Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated PDF
2017.01.10
Press Release
Daiichi Sankyo Announces Reorganization of Research & Development System PDF
2017.01.10
Press Release
Daiichi Sankyo Establishes Strategic Partnership for Cellular Therapy Pipeline with Kite Pharma PDF
2016.12.15
Press Release
Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells -Engaging in Joint Research to Create New Cancer Diagnostic Value and Applying It to Drug Research- PDF
2016.12.13
Press Release
Daiichi Sankyo and DarwinHealth Announce Strategic Partnership to Deploy a Quantitative Systems Biology Discovery Platform to Prioritize Daiichi Sankyo Cancer Enterprise Compounds for Development PDF
2016.12.09
Press Release
Daiichi Sankyo and Maruishi Pharmaceutical Launch Analgesic for General Anaesthesia Remifentanil Intravenous Injection 2mg and 5mg “Daiichi Sankyo” PDF
2016.12.08
Press Release
Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary PDF
2016.12.06
Press Release
Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology PDF
2016.12.02
Press Release
U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer PDF